complement c3a human elisa kit bms2089  (Thermo Fisher)

Journal: The Journal of Clinical Investigation

Article Title: C5aR1 signaling triggers lung immunopathology in COVID-19 through neutrophil extracellular traps

doi: 10.1172/JCI163105

Figure Lengend Snippet: An ELISA assay was performed to measure the concentrations of ( A ) C5a, ( B ) factor Bb, and ( C ) C3a in the BAL fluid from patients with influenza ( n = 16) and patients with COVID- 19 ( n = 16). ( B ) Paired concentrations of ( D ) C5a and ( E ) factor Bb in the plasma and BAL fluid from patients with COVID-19 were determined by ELISA. ( F ) A different cohort from a previously published data set was reanalyzed and the t-SNE analysis of total cells (65,166) from BAL fluid of patients with non-COVID-19 pneumonia ( n = 13) and COVID-19 ( n = 22) is shown. ( G ) Dot plots display the highlighted distribution of C5AR1 for each indicated cell population. ( H ) Violin plots showing the expression levels of C5aR1 in each type of cell from patients with COVID-19 or with non-COVID-19 pneumonia. ( I ) The dot plot depicts the scaled and centered expression of an average cell in each cluster and therefore contains negative and positive values. The average expression reflects the mean expression of C5AR1 in each cluster compared with all other cells. ( J ) Number of cells per cell population [neutrophils (Neu), monocytes/macrophages (Mo/Mac), and dendritic cells (cDC)] that express C5AR1 in the groups of patients with COVID-19 and non-COVID-19 pneumonia. ( K ) Average expression of C5AR1 per cell for each cell population [neutrophils (Neu), monocytes/macrophages (Mo/Mac), and dendritic cells (cDC)] in the groups of patients with COVID-19 and non-COVID-19 pneumonia. Data are shown as the mean ± SEM. P values were determined by 2-tailed unpaired ( A – D , J , and K ) or paired ( D and E ) Student’s t tests followed by Wilcoxon matched-pairs signed rank tests.

Article Snippet: C5a, factor Bb, and C3a ELISA assays were performed using, respectively, the human complement component C5a duoset ELISA kit from R&D Systems (DY2037), the MicroVue Bb plus fragment EIA kit from Quidel (A027), and the Complement C3a human ELISA kit from Thermo Fisher Scientific (BMS2089).

Techniques: Enzyme-linked Immunosorbent Assay, Clinical Proteomics, Expressing

Journal: The Journal of Clinical Investigation

Article Title: C5aR1 signaling triggers lung immunopathology in COVID-19 through neutrophil extracellular traps

doi: 10.1172/JCI163105

Figure Lengend Snippet: ( A ) Tg mice were infected with SARS-CoV-2 (2 × 104 PFU, intranasally). ELISA assay to measure levels of ( B ) C5a in the lung homogenate of infected animals ( n = 14) or mock control ( n = 11). ( C ) factor Bb and ( D ) C3a levels in the lung homogenate of infected animals ( n = 8) or mock control ( n = 5). ( E ) Representative confocal images of the presence of C5aR1 expression in the lung tissue of Tg fl/fl mice ( C5ar1 -eGFP mice) infected with SARS-CoV-2 (5 dpi). Tissue slices were costained for nuclei (DAPI, blue), Iba-1 (macrophages, red) and NE (neutrophils, red) markers. Scale bar: 50 μm. ( F ) Percentage of cells expressing C5aR1 in the lung tissue of Tg fl/fl mice infected with SARS-CoV-2 ( n = 4 mice/4 randomized field). ( G ) Representative H&E staining from the lung of SARS-CoV-2-infected Tg fl/fl ( n = 6) or Tg cKO mice ( n = 6). A mock-infected group was used as control ( n = 6). Scale bars: 200 μm (4 ×), 100 μm(10 ×). ( H ) TUNEL staining (red) for detection of apoptotic cells in situ from lung tissue of SARS-CoV-2–infected Tg fl/fl ( n = 5) or Tg cKO mice ( n = 6). Mock-infected Tg mice were used as a control ( n = 5/group). ( I ) Quantification of the lung septal area fraction. ( J ) Percentage of TUNEL positive cells in lung tissue. Scale bar: 50 μm. ( K ) ELISA assays were performed to detect CCL2, CCL3, CCL4, CXCL1, and IL-6 levels in the lung tissue of Tg fl/f ( n = 8) or Infected Tg cKO mice ( n = 7). Mock-infected Tg mice were used as a control ( n = 5). Data are shown as the mean ± SEM. P values were determined by ( B – D ) Student’s 2-tailed t test and ( F , I , J , and K ) 1-way ANOVA followed by Bonferroni’s posthoc test.

Article Snippet: C5a, factor Bb, and C3a ELISA assays were performed using, respectively, the human complement component C5a duoset ELISA kit from R&D Systems (DY2037), the MicroVue Bb plus fragment EIA kit from Quidel (A027), and the Complement C3a human ELISA kit from Thermo Fisher Scientific (BMS2089).

Techniques: Infection, Enzyme-linked Immunosorbent Assay, Control, Expressing, Staining, TUNEL Assay, In Situ

Journal: The Journal of Clinical Investigation

Article Title: C5aR1 signaling triggers lung immunopathology in COVID-19 through neutrophil extracellular traps

doi: 10.1172/JCI163105

Figure Lengend Snippet: ( A ) Tg mice were infected with SARS-CoV-2 (2 x 104 PFU, intranasally) and treated with DF2593A (3 mg/kg, p.o) 1 hour before SARS-CoV-2 infection and once a day up to the day of sample collection (5 dpi). ( B ) Body weight, clinical score, and oxygen saturation were measured daily after infection ( n = 11/group, pooled from 2 independent experiments). ( C ) Representative H&E staining from the harvested lung of the COVID-19 mouse model treated ( n = 4) or not ( n = 6) with DF2593A. A mock-infected group was used as control ( n = 5). Scale bars: 200 μm (4 ×); 100 μm (10 ×). ( D ) TUNEL staining (green) for detection of apoptotic cells in situ from lung tissue of mice ( n = 5/group). ( E ) Quantification of the lung septal area fraction. ( F ) Percentage of TUNEL-positive cells in lung tissue. Scale bar: 50 μm. ( G ) ELISA assays were performed to detect CCL2, CCL3, CCL4, CXCL1, and IL-6 levels in lung homogenate ( n = 6/group). A mock-infected group was used as the control group. Data are shown as the mean ± SEM. P values were determined by 1-way ANOVA followed by Bonferroni’s posthoc test ( E – G ).

Article Snippet: C5a, factor Bb, and C3a ELISA assays were performed using, respectively, the human complement component C5a duoset ELISA kit from R&D Systems (DY2037), the MicroVue Bb plus fragment EIA kit from Quidel (A027), and the Complement C3a human ELISA kit from Thermo Fisher Scientific (BMS2089).

Techniques: Infection, Staining, Control, TUNEL Assay, In Situ, Enzyme-linked Immunosorbent Assay

Journal: The Journal of Clinical Investigation

Article Title: C5aR1 signaling triggers lung immunopathology in COVID-19 through neutrophil extracellular traps

doi: 10.1172/JCI163105

Figure Lengend Snippet: ( A ) C57/BL6 mice were treated twice with vehicle, DNAse (Pulmozyme, 10 mg/kg, s.c.), or C5aR1 antagonist (DF2593A, 3 mg/kg, orally), 24 hours and 1 hour before the intratracheal instillation of rmC5a (400 ng). ( B ) Lung slices from the control group or mice challenged with rmC5a and treated with vehicle, DNAse, or C5aR1 antagonist (DF2593A) were stained with H&E for evaluation of histological changes. ( C ) Quantification of the lung septal area fraction ( n = 5/group). ( D ) Lung slices from the control group or from mice challenged with rmC5a and treated with vehicle, DNAse, or C5aR1 antagonist (DF2593A) were costained for nuclei (DAPI, blue), H3Cit (green), and MPO (red) markers. ( E ) NET quantification by the MPO-DNA PicoGreen assay in the supernatant of the lung homogenate ( n = 5–6/group). ( F ) ELISA assays were performed to detect CCL2, CCL3, CCL4, CXCL1, and IL-6 levels in lung homogenate ( n = 5–6/group). Data are shown as the mean ± SEM. P values were determined by 1-way ANOVA followed by Bonferroni’s posthoc test ( C , E , and F ).

Article Snippet: C5a, factor Bb, and C3a ELISA assays were performed using, respectively, the human complement component C5a duoset ELISA kit from R&D Systems (DY2037), the MicroVue Bb plus fragment EIA kit from Quidel (A027), and the Complement C3a human ELISA kit from Thermo Fisher Scientific (BMS2089).

Techniques: Control, Staining, Picogreen Assay, Enzyme-linked Immunosorbent Assay